Syneron Medical Appoints Jonathan Pearson as Executive Vice President of
Business Development, Topical Products
YOKNEAM, Israel, Nov. 7, 2012
YOKNEAM, Israel, Nov. 7, 2012 /PRNewswire/ --Syneron Medical Ltd. (NASDAQ:
ELOS), www.syneron.com, the leading global aesthetic device company, announced
today that Jonathan Pearson has been appointed Executive Vice President of
Business Development, Topical Products, effective November 19, 2012. In this
position, Mr. Pearson will have global responsibility for Syneron's business
of topical cosmetic products, which currently includes the elure™ Advanced
Skin Brightening product family. He will report to Louis P. Scafuri, Chief
Executive Officer of Syneron.
Prior to joining Syneron, from 2003 to 2012, Mr. Pearson was a corporate
officer at TRIA Beauty, Inc., a developer and marketer of light-based skincare
products for use in the home. Mr. Pearson was a co-founder of the company and
served as Asia Pacific Region Manager, with direct responsibility for
establishing and managing the company's Asian operations. Prior to co-founding
TRIA Beauty, Mr. Pearson was employed from 2001 to 2003 at Lumenis, Ltd., a
developer, manufacturer and distributor of a broad range of medical lasers and
energy delivery equipment for surgical, aesthetic and ophthalmic applications.
At Lumenis, Mr. Pearson was Executive Vice President, Asia-Pacific Operations,
and served as a corporate officer. Mr. Pearson joined Lumenis when it merged
with Coherent Inc., where he served from 1994 to 2001, ultimately as Director,
Asia-Pacific, managing the company's direct operations in Japan and the
People's Republic of China.
Mr. Pearson holds a bachelor's degree in Political Science from the University
of Washington and a master's degree in International Management from
Thunderbird School of Global Management. He is bi-lingual in the English and
Japanese languages, and has extensive experience living in Asia.
Mr. Scafuri, said, "Jon Pearson has a proven track record of success in the
aesthetic industry, with unique and relevant global experience in both the
professional and consumer markets. We believe he is ideally suited to help us
capitalize on the tremendous opportunity for our elure™ Advanced Skin
Brightening product family, as well as further expand the topical segment of
our business. His deep familiarity with and understanding of Asian markets
will be particularly valuable, given that this geography represents the
largest opportunity for elure™. We look forward to welcoming Jon to the team
and collaborating with him to grow our topical business."
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology, real science and
real results – is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. The Company's aspiration and
commitment to innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin lightening. Founded in
2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical
Ltd. are located in Israel. Syneron also has R&D and manufacturing operations
in the US. The company markets and services and supports its products in 86
countries. It has offices in North America, France, Germany, Italy, Portugal,
Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the company will not meet stated goals, as well as the risks set
forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and
the other factors described in the filings that Syneron Medical Ltd. makes
with the SEC from time to time. If one or more of these factors materialize,
or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s
actual results, performance or achievements may vary materially from any
future results, performance or achievements expressed or implied by these
In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.
Contact: Hugo Goldman, Chief Financial Officer, firstname.lastname@example.org; or
Zack Kubow, The Ruth Group, +1-646-536-7020, email@example.com
Press spacebar to pause and continue. Press esc to stop.